Online inquiry

IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11437MR)

This product GTTS-WQ11437MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NT5E gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001204813.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4907
UniProt ID P21589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11437MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8337MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ5698MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ7788MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ11582MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ15961MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ9173MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ13089MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ5071MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CaCP-29
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW